In a recent article, Cerletti et al. (2008) report the preparation of a new, highly myogenic subset of skeletal muscle satellite cells that bestows functional benefits when grafted into the dystrophic muscles of mdx mice. Cerletti et al. (2008) used FACS to sort these skeletal muscle precursors (SMPs), defined by a number of antigenic markers, from the population of cells adhering to freshly isolated muscle fibers of mice that express green fluorescent protein (GFP) as a genetic label. These SMPs were then grafted into the muscles of normal mice damaged by injection of a toxin or into the muscles of dystrophic mdx mice, which exhibit spontaneous muscle degeneration.
Although the authors do indeed show that SMPs contribute strongly to regeneration when grafted into myotoxindamaged or dystrophic mouse muscles, their claim that SMPs are a discrete stem cell subset of the muscle satellite cell population is, in my view, problematic. SMPs appear to share most of their markers with the major portion of the satellite cell population, and Cerletti et al. do not clearly demonstrate that they are functionally superior to or distinct from the general satellite cell population. In addition, it is not clear whether the SMPs are distinct from the muscle satellite cell population, reported in a previous study (Montarras et al., 2005) , that were isolated on the basis of Pax3-GFP expression or CD34 expression in combination with forward-and side-scatter parameters.
Of greater concern is the claim by Cerletti et al. of functional normalization of successfully grafted muscles (see Figure 5 and Table S1 of Cerletti et al., 2008) . Two functional parameters of muscle physiology were analyzed (the peak tetanic force and the area under the force/time curve), averaged over a sequence of maximal stimuli. Both sets of measurements were normalized to muscle size and so should reflect an intrinsic functional quality of the muscles. But the values plotted against % muscle fibers positive for GFP were the ratios of values for cell-injected muscle and contralateral medium-injected muscle ( Figures 5B and 5C ). Such pairing can be of value when the parameters are consistent between contralateral muscles within the same animal but are expected to vary between animals. Inspection of the raw data (Table S1 of Cerletti et al., 2008) does not point to such a situation nor is any supporting evidence cited.
Superficially, the plots in Figures 5B and 5C of Cerletti et al. (2008) look impressive, with strong correlations between %GFP-positive muscle fibers and the ratio measurements of muscle strength. It is inferred that muscles containing the highest proportion of GFP-expressing myofibers are stronger, exhibiting "up to 5.5-fold greater force production compared to mocktransplanted muscles." This implies a far larger difference between dystrophic mdx muscle and normal muscle than has been reported previously and encourages inspection of the raw data. Averages of normalized peak tension-illustrated here in Figure S1A (available online) as a bar plot of each contralateral muscle pair and of the ratio between them-show that the muscles containing the highest proportion of GFP-positive fibers are not notably stronger and that the muscle-tension traces in Figure 5A are not necessarily representative. In fact, the mean absolute values for the two functional parameters are marginally higher in the sham-injected (25.9) than in the cell-injected (24.25) muscles, arguing against any significant deleterious effect of the sham injections or beneficial effect of the cell injections. What is notable is that those muscles containing the highest proportion of GFPpositive fibers have the highest ratios of peak tension, not because they are particularly strong but because the shaminjected contralateral muscles are unusually weak. This is most conspicuous in the case of the pair of muscles at 87.5% GFP that show the 5.5-fold ratio. Here, the sham-injected control is the second weakest in the series, whereas the strength of the cell-injected contralateral muscle is unexceptional. These data would better support the notion that a successful cell graft in normal muscle weakens the contralateral muscle by 80%. To extend this argument, it should be remembered that the two components of a ratio each carry equal weight. When plotted against its two components, the ratio of cell-injected to sham-injected peak tension clearly shows a stronger inverse relationship with strength in the sham-injected control muscle than its positive association with strength in the treated muscle (see Figure S1B ). This generalizes the conclusion that high ratios between the muscle pairs expressing high GFP levels in the treated muscle are largely attributable to the low values in the sham-grafted control muscle. The other functional parameter considered by the authors, the average area under the curve, shares these same problems.
Hence, I question two of the central claims in the Cerletti et al. (2008) article. I contend that the data presented support neither the notion that a new class of myogenic cell has been isolated nor that successful grafts of this new cell into muscles of dystrophic mdx mice leads to near normalization of muscle function. From previous investigations into the effects of normal myoblast grafts into injured muscle, we would expect some physiological improvement associated with high levels of engraftment within the cell-injected muscles (Arcila et al., 1997; Irintchev et al., 1997) . Visual inspection of the raw data, as presented in Figure S1A shown here, gives some hint of such a relationship, but parametric correlation tests fall short of statistical significance at 5%. Interestingly, nonparametric tests (Spearman's or Kendall's) do reveal ordinal relationships of both functional parameters with %GFP but only indicate trends within the cell-injected muscle series and do not reveal the quantitative relationships involved. Certainly, the attribution of a 5.5-fold increase in muscle strength to cell injection cannot be sustained when the sham-injected control muscle series is the stronger and contains values for both parameters that far exceed those for normal control muscle. This highlights the main problem with these data: the enormous intermuscle variability of the functional parameters, especially among the controls, generates experimental noise that calls into question any detailed statistical analysis. In his Correspondence, Terence Partridge raises two issues regarding our recent study investigating the stem cell properties of FACS-purified skeletal muscle precursors (SMPs) (Cerletti et al., 2008) . First, he challenges our conclusion that SMPs represent a distinct myogenic cell population, and second, he questions our physiological assessment of the SMP-engrafted muscles of dystrophic mdx mice. However, as elaborated below, his point regarding the novelty of our cell isolation strategy is inaccurate, and more importantly, his reanalysis of our functional data uses inappropriate statistical methods that lead him to an erroneous conclusion. First, Dr. Partridge argues that SMPs are not a unique myogenic cell population because (1) SMPs share phenotypic markers with muscle satellite cells, and (2) a previous publication (Montarras et al., 2005) , which he coauthored, isolated a similar population of cells using gene-targeted Pax3-GFP reporter mice and another cellsurface marker (CD34 expression).
We agree that SMPs have properties similar to Pax3-GFP + muscle satellite cells and properly credit this work in our paper (Cerletti et al., 2008, p. 42) . However, Dr. Partridge seems to disregard direct evidence presented in our study that SMPs are a distinct subset of muscle satellite cells. We showed that most SMPs do express the canonical satellite cell marker Pax7, but that SMP markers (β1-integrin and CXCR4) are expressed by only ~80% of Pax7 + cells. Thus, we conclude that SMPs are a subpopulation of satellite cells, which unlike Pax3-GFP + cells (Montarras et al., 2005) do not require specialized transgenic mouse strains for their isolation. More importantly, however, our work rigorously demonstrates distinctive functional and physiological properties of SMPs (Cerletti et al., 2008; Sherwood et al., 2004) , an essential step in the effective characterization of any stem or progenitor cell population (Wagers and Weissman, 2004) . In particular, we have shown that SMPs are the only subset of myofiber-associated cells that exhibits clonal myogenesis in vitro and a robust myogenic contribution in vivo. Our more recent experiments using intramuscular transplantation of single GFP + SMPs further demonstrate that ~50% of muscles transplanted with a single SMP exhibit detectable myofiber engraftment (n = 10 muscles, M.C. and A.W., unpublished data). Given that previous studies indicate that 99% of myogenic donor cells perish almost immediately upon transplant (Beauchamp et al., 1999) , these data clearly indicate that selection for SMP markers yields a unique, highly purified population of cells that is well suited to in vivo cell therapy.
The second concern raised by Dr. Partridge relates to our conclusion that highlevel in vivo engraftment of myofibers by donor SMPs results in improved physiological function in recipient muscles. His challenge is based largely on the fact that we presented our data in a chart that correlated muscle engraftment level with the fold difference in contractile activity of SMP-treated versus mock-treated contralateral muscles in the same animal (see Figure 5 , Cerletti et al., 2008) . We maintain that this is an appropriate method of analysis because the comparison of SMPtreated versus mock-treated muscles in the same mouse accounts for variability in dystrophic disease and in engraftment efficiency in individual mdx recipients. In fact, clinical trials for myoblast transplantation and for exon skipping use similar comparisons to assess treatment efficacy (http://www.clinicaltrials.gov/, reviewed in Cossu and Sampaolesi, 2007) . In any case, we also provided the same data in raw form in the Supplemental Data of our paper (Table S1) .
Using the data in our Table S1 (Cerletti et al., 2008), Dr. Partridge has reanalyzed our results and comes to the conclusion that the only reason our SMP-treated muscles showed improvement is that they were compared to contralateral muscles that were particularly weak. This conclusion is based on replotting of our data using a linear regression model and on parametric correlation tests, which Dr. Partridge states "fall short of statistical significance at 5%" (in fact, the actual values are p = 0.055 and p = 0.056, using Pearson's product-moment correlation, for the specific peak force and the integrated area under the curve, respec-
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